1. Home
  2. RXT vs ADCT Comparison

RXT vs ADCT Comparison

Compare RXT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RXT
  • ADCT
  • Stock Information
  • Founded
  • RXT 1998
  • ADCT 2011
  • Country
  • RXT United States
  • ADCT Switzerland
  • Employees
  • RXT N/A
  • ADCT N/A
  • Industry
  • RXT EDP Services
  • ADCT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RXT Technology
  • ADCT Health Care
  • Exchange
  • RXT Nasdaq
  • ADCT Nasdaq
  • Market Cap
  • RXT 274.9M
  • ADCT 241.0M
  • IPO Year
  • RXT 2020
  • ADCT 2020
  • Fundamental
  • Price
  • RXT $1.17
  • ADCT $3.13
  • Analyst Decision
  • RXT Hold
  • ADCT Strong Buy
  • Analyst Count
  • RXT 5
  • ADCT 6
  • Target Price
  • RXT $1.58
  • ADCT $7.80
  • AVG Volume (30 Days)
  • RXT 824.1K
  • ADCT 643.8K
  • Earning Date
  • RXT 08-07-2025
  • ADCT 08-12-2025
  • Dividend Yield
  • RXT N/A
  • ADCT N/A
  • EPS Growth
  • RXT N/A
  • ADCT N/A
  • EPS
  • RXT N/A
  • ADCT N/A
  • Revenue
  • RXT $2,693,100,000.00
  • ADCT $77,246,000.00
  • Revenue This Year
  • RXT N/A
  • ADCT $11.75
  • Revenue Next Year
  • RXT $1.48
  • ADCT $8.56
  • P/E Ratio
  • RXT N/A
  • ADCT N/A
  • Revenue Growth
  • RXT N/A
  • ADCT 15.73
  • 52 Week Low
  • RXT $1.00
  • ADCT $1.05
  • 52 Week High
  • RXT $3.41
  • ADCT $3.97
  • Technical
  • Relative Strength Index (RSI)
  • RXT 42.17
  • ADCT 57.35
  • Support Level
  • RXT $1.12
  • ADCT $2.56
  • Resistance Level
  • RXT $1.30
  • ADCT $3.23
  • Average True Range (ATR)
  • RXT 0.08
  • ADCT 0.19
  • MACD
  • RXT -0.01
  • ADCT 0.04
  • Stochastic Oscillator
  • RXT 22.73
  • ADCT 83.82

About RXT Rackspace Technology Inc.

Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: